For many people suffering from asthma, the winter months and the colder air can trigger asthma symptoms and flare-ups, which ...

Inhalon Biopharma's inhaled RSV antibody treatment will enter human trials marking a potential breakthrough in respiratory ...

MACE incidence in patients with COPD initiating triple therapy was 11.3/100/year vs 8.7/100/year in patients using LABA-ICS. In patients with chronic obstructive pulmonary disease (COPD), the first ...

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

It is estimated that nearly half of all patients with asthma do not have their condition under control, mainly as a result of poor adherence to inhaler therapy, leading to increased symptoms and ...

Treatment recommendations for chronic obstructive pulmonary disease (COPD) include triple inhaler combination therapy with an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long ...

Inhaler colors often are used to identify specific types of inhalers (such as blue ... Combination medications that include triple therapy drugs (ICS-LAMA-LABA, like Breztri or Trelegy Ellipta). This ...

Objective: Single inhaler triple therapy is widely used in Chronic Obstructive Pulmonary Disease (COPD) and asthma. This research aimed to analyze adverse events (AEs ...

The most common form of treatment that doctors prescribe for COPD is inhalation therapy, which includes inhalers and nebulizers. Compared to traditional medication inhalers, a nebulizer can ...

One red inhaler contains the rescue medication albuterol. Another red inhaler is a combination therapy of a corticosteroid and a LABA. Be sure to read your labels so you take the correct medication.

the RespiRx™, today announced the first patient was dosed in its Phase 1 clinical trial evaluating RespiRx™ Nicotine Inhaler (QN-01) as a smoking cessation therapy in the U.S. Smoking ...

In a statement, the company said the Breztri approval means the device is now approved for use with all triple-therapy inhalers in the US market. Adherium’s chief executive, Dr Paul Mastoridis ...